The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

March 3 (Reuters) - The U.S. Food and Drug Administration has issued warning letters to 30 telehealth companies for making ...

The FDA’s effort to crack down on compounded versions of popular GLP-1 weight-loss drugs has sparked backlash from patients and compounding pharmacies over concerns about access and ...

March 4, 2026 - The U.S. Food and Drug Administration on Tuesday announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 ...

By Mariam Sunny March 3 (Reuters) - Strive Pharmacy said on Tuesday it has no plans to resume sales of a compounded version of Novo Nordisk's oral semaglutide, pushing back on an earlier media report ...

The FDA has issued 30 warning letters to telehealth companies over misleading claims about compounded GLP-1 drugs. Regulators say some companies im ...

The FDA has issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites. The letters cite violations including claims ...

1. FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. FDA News Release. March 3, 2026.

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Add Yahoo as a preferred source to see more of our stories on Google. Hims & Hers’ Super Bowl ad plugs its compounded weight loss drugs as the “affordable” solution to a “sick system,” but many ...